Health Care • Biotechnology: Pharmaceutical Preparations
$4.56 ▲ +0.01
(+0.22%)
MKT CAP: $260.8M • VOL: 874.3K
52W L $4 52W H $8
ABEO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $5.8M | $0 | $3.5M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $4.3M | — | — |
| Gross Margin % | 73.7% | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$89.4M | -$64.2M | -$47.1M |
| Operating Margin % | -80.0% | — | -80.0% |
| Net Income (GAAP) | -$71.2M | $63.7M | $54.2M |
| EBITDA (Normalized) | -$83.1M | -$62.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$76.3M | -$56.0M | -$37.0M |
| Capital Expenditures (CapEx) | $8.0M | $2.4M | — |
| Free Cash Flow (FCF) | -$84.3M | -$58.5M | -$37.0M |
| FCF Margin % | -80.0% | — | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $78.4M | $23.4M | — |
| Total Debt (Short + Long Term) | $7.8M | $13.0M | — |
| Total Stockholders' Equity | $159.2M | $44.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ABEO.